Cooperative Agreement UG1CA308564
Award Date 4/20/26
Completion Date 2/29/32
Dollars Obligated $367K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- Grant Award Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $975,000 to Rutgers The State University of New Jersey on March 21, 2026, under the Cancer Treatment Research program (CFDA 93.395) with a completion date of February 29, 2032. This award supports clinical trial infrastructure and administrative services for the Rutgers Cancer Institute and RWJBarnabas Health System. The initiative facilitates expanded cancer clinical research across multiple...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $922,755 to the University of Massachusetts Medical School on August 28, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate tRNA modification reprogramming and translational remodeling in cancer. The five-year project, scheduled for completion on July 31, 2030, will comprehensively examine how chemical modifications of transfer RNA (tRNA) and their...
- COOPERATIVE AGREEMENT SUMMARY The University of Pennsylvania's Abramson Cancer Center (ACC) received a $368,701 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 20, 2026, through February 29, 2032. This award supports the ACC's Lead Academic Participating Sites (LAPS) initiative, which serves as a centralized hub for the NCI's National Clinical Trials Network (NCTN). Under the direction of Principal...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $639,882 to the University of North Carolina at Chapel Hill (UNC-CH), Office of Sponsored Research, effective August 1, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research into the molecular mechanisms underlying metastasis organ tropism—specifically, why certain breast cancer subtypes preferentially...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $962,104 to the Research Institute at Nationwide Children's Hospital, effective July 3, 2025 through June 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and clinical testing of novel therapeutic approaches targeting mutant-MYOD1 driven rhabdomyosarcoma (RMS), the most common soft tissue cancer in the pediatric population. The...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded $941,798 to Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) on August 6, 2025, for a five-year initiative concluding July 31, 2030. This cooperative agreement supports fundamental research investigating the mechanism and therapeutic implications of RNA-modification-mediated codon-biased translation in acute myeloid leukemia (AML). The research focuses on...
- Cooperative Agreement Summary The National Cancer Institute awarded a $556,865 Cooperative Agreement to Trustees of Tufts College under the Cancer Biology Research program (CFDA 93.396) on September 1, 2025, with a completion date of August 31, 2030. This five-year research initiative investigates stiffness-mediated genetic selection of cells, examining how mechanical properties of substrates select for cellular variants adapted to growth on soft or stiff environments. The research extends...
- Federal Cooperative Agreement Summary The University of Southern California received a $531,693 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on August 4, 2025, with a completion date of July 31, 2030. This award supports research to develop a validated computational model of the tumor-immune ecosystem in breast cancer. The project will deliver an agent-based computational model that captures tumor-immune...
- Federal Project Grant Award Summary The National Cancer Institute awarded Indiana University Indianapolis a $423,084 Project Grant under the Cancer Biology Research program (CFDA 93.396) to investigate the musculoskeletal wasting syndrome associated with metastatic colorectal cancer. The research project, initiated May 5, 2025 and extending through April 30, 2030, focuses on identifying the biological mechanisms by which cancer cachexia—a multi-organ wasting condition responsible for over 30% of...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a Cooperative Agreement totaling $953,922 to Scripps Research Institute, effective September 1, 2025 through August 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research investigating the relationships between ribosomal RNA (rRNA) and transfer RNA (tRNA) modifications, codon usage patterns, translation rates, and metabolic processes in cancer cells. The research...